Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice

Abstract

SummaryThe efficacy and safety of the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg in the treatment of vertigo of various origins have been investigated in a prospective, noninterventional study involving private practices throughout Germany. A total of 1275 patients with an average age of 61.2 years participated in the study. The vertigo symptoms, measured by a validated mean vertigo score (primary efficacy endpoint) improved by 61 % in the course of the observational period (median: 6 weeks). Concomitant symptoms frequently associated with vertigo such as nausea, vomiting and tinnitus were also markedly reduced by 84, 85 and 51 %, respectively. Overall efficacy has been rated by the physicians as ‘very much improved’ or ‘much improved’ in 95 % of the patients. A total of 47 patients (3.7 %) reported 51 adverse drug reactions (all nonserious). The results indicate a good tolerability and efficacy of the fixed combination of cinnarizine and dimenhydrinate in the treatment of vertigo in daily medical practice, which is in line with previous findings of numerous interventional, randomised, double-blind, controlled clinical trials.

Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms

“…In agreement with previous studies conducted by Pytel [51], Scholtz [52], and others, the results of this study provide further insight regarding the efficacy of the aforementioned fixed low-dose combination when used to reduce vestibular vertigo symptoms of central and/or peripheral origin, as measured by the Dizziness Handicap Inventory and the Visual Scale of Dizziness Disorders, after both the 15-day therapy (primary evaluation of the efficacy of pharmacological therapy) and 60-day therapy (primary efficacy endpoint). In particular, independent of the type of vertigo, the fixed-combination treatment was able to reduce dizziness-and vertigo-associated symptoms in more than 75% of all patients treated, starting after 15 days of therapy, and improving 60 days after starting the therapy, to the end of observation.…”

Identification of novel chemotherapeutic strategies for metastatic uveal melanoma

“…As regards the putative drugs here identified, some of them are already in clinical use, such as BRD-K07220430 (Cinnarizine) 24 , clofazimine 25 , mesoridazine besylate 26 , erythromycin ethylsuccinate 27 ; other are in preclinical development (e.g. HDAC6 inhibitor ISOX) 28 or do not have any known pharmacological target, e.g.…”

Negative impact of vestibular suppressant drugs on provocative positional tests of BPPV: A study from the Western Part of India

“…Vestibular suppressant drug (VSD) classes useful in the treatment of vertigo include histamine-1 receptor agonist (betahistine), antihistamines (cinnarizine, dimenhydrinate, meclizine), dopamine receptor antagonists (prochlorperazine), anticholinergics (scopolamine), and benzodiazepines (clonazepam). [ 16 17 ] These drugs may suppress the nystagmus response of BPPV during diagnostic positional tests and are speculated to contribute to patients classified as S-BPPV. [ 18 19 ] The present research aimed to study demographics and clinical profile of O-BPPV and S-BPPV as well as to find the impact of VSD on the provocative positional test (PPT) among BPPV patients.…”